Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective cut by stock analysts at Royal Bank Of Canada from $445.00 to $350.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 72.32% from the company’s current price.

Several other equities analysts also recently commented on ALNY. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Friday. Bank of America lowered their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. JPMorgan Chase & Co. reduced their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $418.48.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $2.38 during trading hours on Friday, hitting $203.10. 2,668,101 shares of the company’s stock were exchanged, compared to its average volume of 1,369,454. Alnylam Pharmaceuticals has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The firm has a market cap of $27.12 billion, a P/E ratio of 55.56 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The firm has a 50 day moving average of $289.80 and a two-hundred day moving average of $312.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. Sell-side analysts forecast that Alnylam Pharmaceuticals will post 7.35 EPS for the current year.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 6.1% in the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after purchasing an additional 151,480 shares in the last quarter. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $895,816,000. Orbis Allan Gray Ltd lifted its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Alnylam Pharmaceuticals by 8.3% in the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after buying an additional 73,716 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 23.6% in the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after buying an additional 175,951 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Several analysts retained bullish ratings despite reducing their targets. Oppenheimer lowered its target to $350 while maintaining “outperform,” Stifel cut its target to $318 while keeping a “buy” rating, Needham reduced its target to $357 with a “buy” rating, and Chardan reaffirmed “buy” with a $425 target. These targets imply considerable potential upside if Alnylam’s growth outlook stabilizes. Analyst price-target updates
• Neutral Sentiment: Alnylam reported second-quarter adjusted earnings of $1.84 per share, up from $0.32 a year earlier, while revenue increased 66.9% to $1.29 billion. However, reported revenue was below the $1.32 billion consensus estimate, and earnings estimates vary by data provider. Alnylam second-quarter earnings report
• Negative Sentiment: The main pressure came from a reduction to 2026 product-sales guidance and commentary that second-line Amvuttra demand is normalizing. Investors viewed the weaker ATTR outlook as outweighing record Amvuttra quarterly sales, prompting concerns about the pace and durability of future growth. Alnylam lowers 2026 outlook
• Negative Sentiment: Shareholder-rights law firms announced securities-fraud investigations following the selloff. The announcements may add reputational and legal overhang, although they do not establish wrongdoing by Alnylam. Securities-fraud investigation announcement

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.